Q-omics provides the consensus-scored OTX2-AS1 profile across patient tissues and cancer cell-line models. OTX2-AS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, OTX2-AS1 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, OTX2-AS1 RNA expression shows 8,431 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, KIRP, and TGCT as cancer lineages where OTX2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTX2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTX2-AS1 survival associations across molecular data types. OTX2-AS1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTX2-AS1 RNA expression–survival associations across cancer types. High OTX2-AS1 expression shows unfavorable associations in KICH, COAD, DLBC and CHOL, but favorable associations in LUSC and ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for OTX2-AS1 RNA expression.
This table summarizes OTX2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for OTX2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTX2-AS1 shows higher tumor expression in KIRP, LUSC, LIHC and CHOL. The KIRP box plot shows higher OTX2-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .020).
This table shows molecular features associated with OTX2-AS1 in patient tissues and cancer cell lines. In patient samples, OTX2-AS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
